- Investing Ideas
- /
- Global Pharmaceuticals & Biotech Inefficient Market Opportunities
Global Pharmaceuticals & Biotech Inefficient Market Opportunities
Results
4
Less coverage brings about more information asymmetry and more opportunities to buy mispriced stocks. Companies valued at less than US$500M with low PE and PEG.
4 companies
Abeona Therapeutics
Market Cap: US$364.7m
A clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases.
ABEO
US$7.13
7D
13.9%
1Y
42.6%
Protalix BioTherapeutics
Market Cap: US$118.0m
A biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system.
PLX
US$1.48
7D
-3.9%
1Y
52.4%
Decibel Cannabis
Market Cap: CA$69.2m
An integrated cannabis company, engages in the cannabis cultivation in Canada.
DB
CA$0.12
7D
14.3%
1Y
100.0%
Neuphoria Therapeutics
Market Cap: US$15.2m
A clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia.
NEUP
US$8.10
7D
9.0%
1Y
n/a